Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References

Note: This list includes important publications related to incretin-based therapy, including some that are not cited in the activity “Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes.”

General


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


GLP-1 Agonists

General


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


**Exenatide Twice Daily**


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


Liraglutide


Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group,
Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


**Exenatide Once Weekly**


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


**Lixisenatide** [Not approved for use in the United States when this document was prepared]


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References

DPP-4 Inhibitors

General


Sitagliptin

Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


Nauck MA, Meininger G, Sheng D, et al; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a
References


**Saxagliptin**

Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References

523.


**Linagliptin**


Jentadueto™ (linagliptin and metformin hydrochloride) tablets. Prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2012.


Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and
Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


**Alogliptin**


Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References


**Vildagliptin [Not approved for use in the United States]**


Galvus (vildagliptin 50 mg tablets). Summary of product characteristics. London: European Medicines Agency; June 2012. Available at:
Incretin-Based Therapy: Evolving Treatment Strategies for Type 2 Diabetes

References

